Interestingly, after treatment with ERBB inhibitors, the expected increase in proliferation, migration, and invasion abilities of liver cancer cells were suppressed, accompanied by a notable decrease in the expression levels of ERBB2 and its downstream signaling pathways. This evidence concerns the gene ERBB2 and liver cancer.